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Introduction
When vagus nerve stimulation (VNS) therapy (Cyberonics; Houston, TX) was approved by the US Food and Drug Administration (FDA) in 1997, the system was ''indicated for use as an adjunctive therapy in reducing the frequency of seizures in adults and adolescents over 12 years of age with partial onset seizures that are refractory to antiepileptic medications.'' 1 VNS therapy is delivered by a pulse generator implanted in the chest and connected to the left vagus nerve with a lead ending with electrodes. The stimulation is delivered in ON and OFF cycles around the clock at an intensity determined and set by the clinician. The patient or caregiver who senses an oncoming seizure may activate an extra burst of stimulation with a hand-held magnet in an attempt to abort or diminish the seizure. Results of the pivotal ran-domized clinical trial (E05) after 12 months 5 of VNS therapy for partial-onset seizures as well as 3-year follow-up for 440 evaluable patients 8 (E01-E05) are well documented. Since FDA approval, several studies have suggested that VNS therapy may also be effective for patients with pharmacoresistant generalized epilepsy syndromes. 4, 6, 7 We undertook this study to examine the outcome of VNS therapy among adult patients with well-documented, pharmacoresistant, generalized epilepsy syndromes.
Methods
The University of Washington Human Subjects Committee approved this study and the US FDA granted an Investigational Device Exemption. Inclusionary criteria required a diagnosis of generalized epilepsy syndrome, either idiopathic or symptomatic (in accordance with ILAE classification). 2, 3 Diagnosis was on the basis of clinical data, MRI findings, and long-term EEG-video monitoring. Participants had at least six pharmacoresistant seizures per month during the 3 months before enrollment in the study, were aged 12 years or older, and on a stable regimen of one or more antiepileptic drugs (AEDs).
Patients were excluded from the study for any progressive neurologic disease other than epilepsy or a history of active cardiac or pulmonary disease; peptic ulcer; cervical vagotomy; gastric surgery; substance abuse within the previous year; self-mutilation; suicidal attempts; general anesthesia within the previous 3 months; using an investigational device or drug; previous VNS therapy or brain stimulation; swallowing dysfunction or hospitalization for aspiration pneumonia; likelihood of requiring hospitalization or MRI with body coil; or being on the ketogenic diet during the 3 months immediately before enrollment.
Study protocol
At the first clinic visit, investigators obtained a detailed patient history and performed a clinical examination. Patients meeting inclusionary criteria were followed for 3 months to obtain baseline seizure frequencies. Each patient or caregiver maintained daily diaries of seizure counts for each seizure type. To help ensure the accuracy of seizure diaries, caregivers viewed videotaped episodes of the patient experiencing each type of seizure.
After the baseline phase, the VNS therapy pulse generator and leads were implanted and VNS therapy was initiated 1 week later. Standard settings were employed: 30 Hz, 500 s, 30 s ON, 5 min OFF, magnet ON at 500 s. The output current, initially set at 0.25 mA, was increased weekly by 0.25 mA increments to 1.25 mA. After the ramp-up phase, patients were seen monthly to collect seizure information and interrogate the pulse generator. VNS therapy setting was adjusted, if necessary, to allow for side effects. Output current was increased if greater response was desired and stronger stimulation could be tolerated. Patients were maintained on stable AED regimens.
Data analyses
Data were collected regarding clinical characteristics and changes in seizure frequency. Percent change in seizure frequency between baseline and follow-up were calculated for all seizures and by seizure type. Monthly seizure counts were 3-month averages both pre-and post-implantation. Upper and lower limits of changes in seizure frequency were bounded at 100 and −100%, respectively. Wilcoxon's signed rank tests for non-parametric data were used to test hypotheses of no change in seizure frequency. Values of P ≤ 0.05 were considered statistically significant. All analyses were performed using SAS ® , Version 8. 
Results
Of the 16 patients enrolled in the study, 8 patients had idiopathic (IGE) and 8 had symptomatic generalized epilepsy (SGE) syndromes. Ages of the 9 men and 7 women ranged from 20 to 66 years and averaged 36 years (S.D. ± 11.3). Average age at seizure onset was 7.5 years (S.D. ± 4.8) and epilepsy duration ranged from 6 to 49 years ( Table 1) . Most of the patients were not employed outside their homes, all lived with some type of caregiver, and all had some degree of cognitive impairment. Follow-up after implantation ranged from 12 to 21 months.
Before enrollment, patients had tried and discontinued for lack of effectiveness a mean of 7.5 AEDs (range, 2-15). Gabapentin, carbamazepine, phenobarbital, and diazapam were the most frequently tried and discontinued AEDs. During the study, patients took a mean of 2.69 AEDs (range, 1-5) with dosages remaining stable. Valproic acid, lamotrigine, lorazepam, and topiramate were most frequently prescribed. Table 1 lists patient demographics, clinical characteristics, and changes in seizure frequency. Fig. 1 provides median percentages of seizure reductions from baseline: overall, by syndrome, and by type with marked decreases in seizure types featuring patient falls. Fig. 2 shows changes in monthly Figure 1 Median percent reduction in seizure frequency between baseline and follow-up by seizure syndrome and seizure type. Median percent reduction in seizure frequency of all seizures and all patients, by syndrome, and by seizure type. * Statistically significant (P ≤ 0.05) Wilcoxon's signed rank test. Abbreviations: IGE--idiopathic generalized epilepsy; SGE--symptomatic generalized epilepsy; GTC--generalized tonic-clonic. The difference in seizure frequency reductions was not statistically significant between the two epilepsy syndromes (P = 0.958, Wilcoxon rank sum test). At the end of the study, 43.8% (7 of 16) of the patients had at least a 50% reduction in overall seizure frequency as compared with baseline, including 31.3% (5 of 16) with at least a 75% reduction and 18.8% (3 of 16) with at least a 90% reduction. An additional 18.8% (3 of 16) reported seizures reduced by 25-49%, and another 31.3% (5 of 16) reported changes ranging from decreases of less than 25% to increases of less than 25%. Seizure frequency increased at least 25% in one patient.
The magnet was useful in aborting or reducing the severity of some seizures in 25% (4 of 16 patients). Adverse events associated with VNS therapy, voice change or hoarseness (14 patients), throat pain with stimulation (3), swallowing complaints (2), cough (1), were mild and resolved after several weeks.
Discussion
The reduction in overall seizure frequency in our study supports previous reports of the effectiveness of VNS therapy for both generalized and partial seizures. At follow-up of 12-21 months, the patients in our study of generalized seizures experienced a 43.3% median reduction in seizure frequency. This reduction is similar to the 46% median reduction noted among the 24 patients with generalized seizures after 3 months of VNS therapy during the open-label (E04) clinical trial. 6 Although our study involved generalized seizures, the median seizure reduction was similar to the 45% noted for 114 patients at 12 months after the initial double-blind portion of the E05 clinical trial investigating VNS therapy for partial-onset seizures. 5 The wide range of endpoints and numbers of patients preclude a precise comparison of these studies, but the similarity in reduction of seizure frequency of both partial-onset and generalized seizures is notable.
Three patients in our study experienced seizure frequency reductions of 90% or more, which is especially impressive, considering the established pharmacoresistance of these patients. Also important to the clinician were the marked decreases in the frequency of seizures that may involve a fall or collapse. The nine patients with myoclonic seizures experienced a statistically significant 60% reduction in their frequency. Although not statistically significant, the reductions in the frequency of tonic, atonic, and clonic seizures are clinically important. Reductions in the frequency of such seizures lessen the likelihood of patient injury.
This study used two techniques to enhance the accuracy of the information that was collected. The first technique assured that the patients participating in the study were properly classified as having a generalized seizure syndrome by using video monitoring to establish and verify the seizure syndrome and seizure type experienced by each patient. The second technique involved assuring accurate seizure counts and classification in patient seizure diaries. Before the patients were implanted with the VNS therapy device, caregivers and family members observed videotapes of the patient as the various types of seizures occurred. Implementing these techniques helped assure the quality of the study data.
A definite strength of this study was that AEDs and their dosages remained constant throughout the reported evaluation period. During the long-term, open label phases of the clinical trials of VNS therapy for epilepsy, physicians were allowed to adjust AEDs and their dosages. Long-term follow-up of 67 patients with reported AED changes in the E01 through E04 clinical trials showed the number of AEDs had decreased for 12 patients after the first year and for 18 patients after the second year, and had increased for three patients after the first year and eight patients after the second year. 8 Such changes in AED therapy invite speculation regarding the factors that might influence reductions in seizure frequency or severity. Because AEDs and dosages remained constant, the reductions in seizure frequency and severity noted in the current study can be attributed to the effects of VNS therapy. To our knowledge, this study is the longest prospective investigation of VNS therapy during which concurrent AEDs and their dosages were not changed.
Only 16 patients participated in this study and the duration of follow-up ranged from 12 to 21 months, factors that limit our ability to draw precise comparisons with previously published results of VNS therapy. Despite these limitations, this study supports previous findings that VNS therapy is effective for treating generalized seizures. Because epilepsy surgery is not typically an option for patients with generalized epilepsy, the possibility of seizure reductions with VNS therapy is particularly important. As shown in this study, the statistically significant reduction in overall seizure frequency and the reduced risk of injury during severe seizures merit consideration of VNS therapy for patients with pharmacoresistant generalized seizure syndromes.
